We next examined the association between TMB and PD-L1 expression and oncogenic driver mutations in known driver genes of NSCLC including ALK, EGFR ̧ MET, BRAF, ROS1, ERBB2, and KRAS. To detect associations, we tested for differences in TMB and PD-L1 between tumors with known driver mutations compared to tumors with non-driver mutations in the same gene and tumors without any alterations in any known driver genes of NSCLC (driver gene negative) (Figure 2; Supplementary Figure S1; Supplementary Tables S3, S4). This evidence concerns the gene KRAS and non-small cell lung carcinoma.